
Verastem Oncology Issues Inducement Grants Under Nasdaq Rule 5635(c)(4)
Verastem Oncology a clinical-stage biopharmaceutical company dedicated to the development and commercialization of novel therapies for patients with cancers driven by aberrations in the RAS/MAPK signaling pathway, today announced the…












